Status:
RECRUITING
A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)
Lead Sponsor:
Priovant Therapeutics, Inc.
Conditions:
Cutaneous Sarcoidosis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adults subjects (18-74)
- Cutaneous sarcoidosis with characteristic skin biopsy histology
- A CSAMI activity score ≥ 10
- Weight \> 40 kg to \< 130 kg with BMI \< 40 kg/m2 .
- Exclusion Criteria
- History of
- Lymphoproliferative disorder
- Active malignancy;
- History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix).
- High risk of thrombosis or cardiovascular disease
- High risk of herpes zoster
- Active or recent infection
Exclusion
Key Trial Info
Start Date :
April 9 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT06978725
Start Date
April 9 2025
End Date
December 1 2026
Last Update
May 18 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Trial Site
San Francisco, California, United States, 94115
2
Clinical Trial Site
Durham, North Carolina, United States, 27703
3
Clinical Trial Site
Philadelphia, Pennsylvania, United States, 19104
4
Clinical Trial Site
Madison, Wisconsin, United States, 53715